Third, prospectively quantified IL-17 production by blood T cells predicts the response to IVIg treatment in ICAM-1-/-NOD mice and intraneural IL-17 production is enhanced preferentially in early stage human CIDP patients. The gene discussed is ICAM1; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.